Skip to content

    Zydus Lifesciences Limited

    ZYDUSLIFE
    Healthcare·27 May 2025
    Management Summary

    Zydus Lifesciences concluded FY25 on a strong note, reporting robust double-digit growth in revenues and achieving its highest-ever operating profit and margins. The US business, India formulations, and consumer wellness segments all contributed positively. While the company anticipates continued growth across geographies, FY26 EBITDA margins are guided lower due to competitive pressures on key products and increased R&D. The company is actively expanding its specialty and innovation pipeline, including new product launches and strategic acquisitions like Amplitude Surgical SA.

    Highlights

    5
    • FY25 consolidated revenues of ₹232.4 billion, up 19% YoY, exceeding expectations.

    • Highest ever operating profit and margins in FY25, with EBITDA of ₹70.6 billion, up 31% YoY, and operating margin of 30.4%, up 290 bps.

    • Strong balance sheet with net cash position of ₹48.8 billion as of March 31, 2025, compared to ₹8.6 billion last year.

    • US business delivered sound double-digit growth throughout the year, with Q4 revenues up 24% YoY to ₹31.3 billion.

    • India branded formulations and consumer wellness businesses outpaced market growth, with India geography growing 13% YoY in Q4 FY25.

    Concerns

    3
    • Guidance for FY26 EBITDA margins is around 26%, a decrease from FY25's 30.4%, primarily due to Revlimid competition, Asacol loss, and higher R&D expenses.

    • Impairment taken on Rotigotine product (acquired from Teva) and goodwill related to the Brazil business due to litigation and changed market scenario.

    • Revlimid sales are expected to have peaked in FY25, and FY26 sales will be lumpy and spread across quarters, with potential price erosion.

    What Changed1

    vs Q1 FY26

    Guidance items12 → 11 (-1)
    Key financials

    Metrics

    8

    Periods

    4

    Q4 FY25

    3
    • Consolidated Revenue
      $65.3B
      YoY+18%QoQ+24%
    • EBITDA Margin
      32.6%
    • EBITDA
      $21.3B
      YoY+30%QoQ+53%

    FY25

    3
    • Consolidated Revenue
      $232.4B
      YoY+19%
    • Consolidated EBITDA
      $70.6B
      YoY+31%
    • Operating Margin
      30.4%

    Adj. FY25

    1
    • Net Profit
      $47.5B
      YoY+22%

    Adj. Q4 FY25

    1
    • Net Profit
      $13.9B
      YoY+18%QoQ+36%

    Segment breakdown

    US Business
    31.3 billion rupees Revenue (Q4 FY25)
    India Geography (Formulations & Consumer Wellness)
    39% Revenue Contribution (Q4 FY25)13% Revenue Growth (Q4 FY25)
    Branded Formulations (India)
    11% Revenue Growth (Q4 FY25)
    Consumer Wellness Business
    9.1 billion rupees Revenue (Q4 FY25)13% Volume Growth (Q4 FY25)
    International Markets Formulations
    5.5 billion rupees Revenue (Q4 FY25)
    List

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Debt

    Net ₹48.8 billion rupees

    M&A

    Naturell (India) Pvt. Ltd.

    acquisition · integrated

    M&A

    Amplitude Surgical SA, France

    acquisition · pending regulatory

    M&A

    Zokinvy

    acquisition · integrated

    Liquidity

    Cash ₹48.8 billion rupees

    Net cash position strengthened from ₹8.6 billion in FY24 to ₹48.8 billion in FY25.

    Guidance & targets

    11
    CategoryTargetPriority
    Profitability
    EBITDA Margins
    around 26%
    High
    R&D
    R&D Expenses as % of Revenue
    8%
    High
    Revenue
    US Business Growth
    single digit
    High
    Revenue
    Overall Business Growth
    double-digit growth
    High
    Revenue
    India Business Growth
    better than market
    Medium
    Product Launches
    New Product Launches
    14 to 15 important, critical launches
    High
    Product Launches
    Annual Product Launches
    20-25 products
    High
    NCE Development
    Usnoflast Phase II(b) Clinical Trial
    USFDA approval received
    High
    NCE Development
    Saroglitazar Magnesium for PBC
    Phase II(b)/III trial read-out
    High
    Vaccines
    Bivalent TCV vaccine
    Approval to initiate Phase 2 clinical trial
    High
    Specialty Business
    505(b)(2) oncology product NDA filing
    likely to be filed in 2026
    High

    Mirabegron litigation progress

    Next quarter (leading up to Feb 2026)
    CurrentNext trial scheduled for February 2026
    TargetNo adverse rulings or supply disruptions

    Why it matters

    Mirabegron is a significant new product launch contributing to US growth, and litigation outcome will impact its future sales.

    So, I think, with respect to supplies, we continue to supply the product into the US market. The next trial is scheduled for February of 2026, and which is related to the 780 patent and other asserted patents. So, we will be preparing for the February jury trial.

    How to verify

    qa_highlights[topic='Mirabegron litigation and supply plans']

    Risks & concerns

    4
    RiskSeverity

    Mirabegron litigation

    Next trial scheduled for February 2026 related to 780 patent and other asserted patents. Management believes risk-reward profile has not changed and will continue supply.Analyst acknowledged

    medium

    Revlimid competition and price erosion

    Challenges in pricing and competition for Revlimid are a key driver for lower FY26 EBITDA margin guidance. Sales are expected to be lumpy and have mostly peaked in FY25.Management acknowledged

    high

    Loss of Asacol sales

    Loss of Asacol since last year contributes to the anticipated lower FY26 EBITDA margins.Management acknowledged

    medium

    US tariffs on pharmaceuticals

    Potential impact from US imposing tariffs on pharmaceuticals, though specifics are uncertain. Company is exploring co-development and manufacturing in the US/Europe.Analyst acknowledged

    medium

    Q&A highlights

    7

    “So, I think, with respect to supplies, we continue to supply the product into the US market. The next trial is scheduled for February of 2026, and which is related to the 780 patent and other asserted patents. So, we will be preparing for the February jury trial.”

    Clarifies the ongoing supply strategy and timeline for the next legal challenge for a key product.

    asked by Damyanti Kerai

    2 min read6 chapters

    Detailed Narrative

    01

    Strong FY25 Performance Driven by Growth Across Segments

    Zydus Lifesciences delivered a robust performance in FY25, with consolidated revenues reaching ₹232.4 billion, marking a 19% year-on-year growth. The company achieved its highest-ever operating profit and margins, with EBITDA growing 31% to ₹70.6 billion and operating margin expanding by 290 basis points to 30.4%. This strong profitability also significantly strengthened the balance sheet, moving from a net cash position of ₹8.6 billion in FY24 to ₹48.8 billion in FY25.

    02

    Q4 FY25 Momentum and Margin Expansion

    The fourth quarter of FY25 continued this strong trajectory, with consolidated revenues of ₹65.3 billion, up 18% year-on-year and 24% quarter-on-quarter. Operating profitability saw significant improvement, with an EBITDA margin of 32.6%, an increase of 310 basis points year-on-year and 630 basis points quarter-on-quarter. EBITDA for the quarter stood at ₹21.3 billion, up 30% year-on-year and 53% sequentially, while net profit (adjusted) was ₹13.9 billion, up 18% year-on-year and 36% sequentially.

    03

    US Business and India Formulations Outperform

    The US business registered revenues of ₹31.3 billion in Q4 FY25, growing 24% year-on-year and 30% quarter-on-quarter, driven by volume expansion and new product launches. The India geography, comprising formulations and consumer wellness, accounted for 39% of total revenues and grew 13% year-on-year. The branded formulation business in India grew 11% year-on-year, outpacing the market, with the chronic portfolio now contributing 43% as per IQVIA MAT March 2025, an improvement of 400 basis points over three years.

    04

    Strategic Focus on Specialty, Innovation, and Medtech

    Zydus is expanding its specialty footprint in the US with 505(b)(2) products and a focus on pediatric rare diseases. The company's innovation pipeline is progressing, with USFDA approval for Phase II(b) clinical trial of Usnoflast and an expected read-out for Saroglitazar Magnesium for PBC by year-end. A significant strategic move includes the acquisition of a majority stake in Amplitude Surgical SA, France, marking an entry into the Medtech space, which is expected to be accretive for FY26-27.

    05

    FY26 Outlook: Growth with Margin Adjustment

    For FY26, Zydus anticipates double-digit revenue growth overall, with the US business expected to grow in single digits and India business to outperform the market. However, EBITDA margins are guided to be around 26%, a reduction from FY25's 30.4%. This adjustment is attributed to competitive pressures on products like Revlimid, the loss of Asacol sales, and an increase in R&D expenses, which are projected to be 8% of revenue for FY26.

    06

    Product Pipeline and Regulatory Milestones

    The company continues to focus on new product introductions, with 3 ANDAs filed, 6 approvals received, and 5 new products launched in Q4 FY25. In the vaccine R&D space, Zydus initiated development of a combination vaccine against shigellosis and typhoid with Gates Foundation support and received approval for a Phase 2 clinical trial for its Bivalent TCV vaccine. An exclusive development and commercialization agreement with Synthon BV for a novel 505(b)(2) oncology product, with NDA filing likely in 2026, further strengthens the specialty pipeline.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.